Pharmaceutical companies in Canada have responded to controversial new pricing regulations by cutting staff and withdrawing products from health technology appraisal processes. Potential changes to draft guidelines that set out how the regulations will work in practice will be well received but should go further, says Arvind Mani, founder of Morse, a Canada-based consultancy firm.
The Patented Medicines Prices Review Board (PMPRB), which sets ceiling prices in Canada, told the Pink Sheet that it was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?